| scholarly article | Q13442814 |
| P50 | author | Keith D. Robertson | Q55303090 |
| P2093 | author name string | K D Robertson | |
| P A Jones | |||
| P2860 | cites work | Wild-type p53 binds to the TATA-binding protein and represses transcription | Q24300991 |
| E2F-6, a member of the E2F family that can behave as a transcriptional repressor | Q24317400 | ||
| ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways | Q24321528 | ||
| A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 | Q24322196 | ||
| Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
| Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence | Q24650807 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| CpG islands in vertebrate genomes | Q27861045 | ||
| CpG-rich islands and the function of DNA methylation | Q28131800 | ||
| The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 | Q28266637 | ||
| Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest | Q28270478 | ||
| Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 | ||
| Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer | Q28285050 | ||
| A novel p16INK4A transcript | Q28288161 | ||
| Complex structure and regulation of the P16 (MTS1) locus | Q28293032 | ||
| Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma | Q28300339 | ||
| Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation | Q43993308 | ||
| Promoter occlusion prevents transcription of adenovirus polypeptide IX mRNA until after DNA replication | Q45167232 | ||
| Role of transcriptional interference in the Drosophila melanogaster Adh promoter switch. | Q52247655 | ||
| Role of the INK4a locus in tumor suppression and cell mortality. | Q53455197 | ||
| Transcriptional activation by p53 correlates with suppression of growth but not transformation. | Q53468212 | ||
| 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers | Q55480673 | ||
| Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine | Q67530751 | ||
| Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers | Q71729088 | ||
| Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing | Q71729092 | ||
| Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas | Q73555144 | ||
| The p53-mdm-2 autoregulatory feedback loop | Q28609811 | ||
| Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product | Q28645822 | ||
| Cancer cell cycles | Q29547756 | ||
| Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 | Q29615851 | ||
| mdm2 expression is induced by wild type p53 activity | Q29618316 | ||
| Participation of p53 protein in the cellular response to DNA damage | Q29618319 | ||
| p53: puzzle and paradigm | Q29618407 | ||
| The "initiator" as a transcription control element | Q29619589 | ||
| Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF | Q29619663 | ||
| De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines | Q33738027 | ||
| Germline p16 mutations in familial melanoma | Q34059915 | ||
| Tumor-suppressive pathways in pancreatic carcinoma. | Q34739925 | ||
| Database of p53 gene somatic mutations in human tumors and cell lines | Q34868968 | ||
| Sequence-specific transcriptional activation is essential for growth suppression by p53. | Q35086763 | ||
| Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. | Q35960464 | ||
| Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. | Q36555784 | ||
| DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways | Q36647845 | ||
| Distinct roles for E2F proteins in cell growth control and apoptosis | Q36653915 | ||
| Transcription initiation from the dihydrofolate reductase promoter is positioned by HIP1 binding at the initiation site | Q36717640 | ||
| Negative regulation of the human epsilon-globin gene by transcriptional interference: role of an Alu repetitive element | Q36722061 | ||
| Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population | Q37409666 | ||
| Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression | Q37421517 | ||
| The initiator directs the assembly of a transcription factor IID-dependent transcription complex | Q37593329 | ||
| Wild-type p53 can down-modulate the activity of various promoters | Q37617210 | ||
| Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island | Q38303631 | ||
| Trans-acting protein factors and the regulation of eukaryotic transcription: lessons from studies on DNA tumor viruses | Q39645341 | ||
| Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). | Q39877574 | ||
| Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. | Q39880772 | ||
| Inhibition of viral and cellular promoters by human wild-type p53 | Q40066650 | ||
| An analysis of genes regulated by the multi-functional transcriptional regulator Yin Yang-1. | Q40523037 | ||
| Characterization of the human p53 gene promoter | Q40648046 | ||
| Parental imprinting of autosomal mammalian genes | Q40672445 | ||
| Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product | Q40805644 | ||
| Tumor-suppressor p53 and the cell cycle | Q40886481 | ||
| DNA tumor virus transforming proteins and the cell cycle | Q40886495 | ||
| p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression | Q41007289 | ||
| The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. | Q41056466 | ||
| Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines | Q41072124 | ||
| Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines | Q41128268 | ||
| p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro | Q41167926 | ||
| Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. | Q41228119 | ||
| Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. | Q41429095 | ||
| Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. | Q41553241 | ||
| Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. | Q41643433 | ||
| Splicing into senescence: the curious case of p16 and p19ARF. | Q41657944 | ||
| Transcriptional regulation of the human PAX6 gene promoter | Q42528945 | ||
| Genetic determinants of p53-induced apoptosis and growth arrest | Q42812233 | ||
| Growth regulation of a cellular tumour antigen, p53, in nontransformed cells | Q42819146 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA methylation | Q874745 |
| CpG island | Q1138360 | ||
| gene silencing | Q1431332 | ||
| P304 | page(s) | 6457-6473 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Molecular and Cellular Biology | Q3319478 |
| P1476 | title | The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. | |
| P478 | volume | 18 |
| Q39900588 | 8-Chloro-adenosine-induced E2F1 promotes p14ARF gene activation in H1299 cells through displacing Sp1 from multiple overlapping E2F1/Sp1 sites |
| Q24792846 | A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines |
| Q36216471 | A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. |
| Q42467310 | A distance difference matrix approach to identifying transcription factors that regulate differential gene expression |
| Q34366624 | A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner |
| Q35273882 | A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition |
| Q37075317 | ARF induces autophagy by virtue of interaction with Bcl-xl. |
| Q41914293 | ARF induction in response to DNA strand breaks is regulated by PARP1. |
| Q37155201 | ARF, autophagy and tumor suppression. |
| Q89562496 | Aberrant DNA Methylation of Two Tumor Suppressor Genes, p14ARF and p15INK4b, after Chronic Occupational Exposure to Low Level of Benzene |
| Q41317440 | Aberrant DNA methylation of ESR1 and p14ARF genes could be useful as prognostic indicators in osteosarcoma |
| Q61801116 | Aberrant Expression of p14 in Human Cancers: A New Biomarker? |
| Q52545817 | Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. |
| Q54623978 | Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. |
| Q48258599 | Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas |
| Q55298720 | Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas. |
| Q40604741 | Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation |
| Q57562816 | Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2 |
| Q28242705 | Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation |
| Q53407245 | Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. |
| Q40797012 | Alterations in p53 and E2F-1 function common to immortalized chicken embryo fibroblasts |
| Q40739242 | Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines |
| Q44493023 | Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma |
| Q33988438 | Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation |
| Q74332958 | Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer |
| Q33922894 | Animal models of melanoma: recent advances and future prospects |
| Q37011615 | Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. |
| Q42471717 | Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene |
| Q34520432 | Apoptosis: a link between cancer genetics and chemotherapy |
| Q28535099 | Arf induction by Tgfβ is influenced by Sp1 and C/ebpβ in opposing directions |
| Q33323063 | Association of interindividual differences in p14ARF promoter methylation with single nucleotide polymorphism in primary colorectal cancer |
| Q35014385 | Awakening guardian angels: drugging the p53 pathway |
| Q39674825 | BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets |
| Q28513038 | Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis |
| Q35098096 | Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells |
| Q34286570 | Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts |
| Q24554436 | CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase |
| Q34364651 | CDK5RAP3 is a novel repressor of p14ARF in hepatocellular carcinoma cells. |
| Q35551103 | Cancer epigenetics |
| Q73078903 | Caspase-dependent apoptosis by ectopic expression of E2F-4 |
| Q28609756 | Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b) |
| Q48350837 | Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues |
| Q21092443 | Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression |
| Q40126904 | Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. |
| Q36930013 | Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma |
| Q52541204 | Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. |
| Q41714392 | Control of organ-specific demethylation by an element of the T-cell receptor-alpha locus control region |
| Q33337445 | CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future |
| Q35776918 | CpG methylation as a mechanism for the regulation of E2F activity |
| Q46561692 | DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function |
| Q33875819 | DNA methylation and cancer |
| Q30993657 | DNA methylation, methyltransferases, and cancer |
| Q28140428 | DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters |
| Q59072534 | Death and methylation |
| Q34081815 | Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation |
| Q35941628 | Deregulation of the cell cycle by the Epstein-Barr virus |
| Q48371909 | Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets |
| Q33997846 | Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress |
| Q73800193 | Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status |
| Q40111777 | Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas |
| Q28576734 | Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells |
| Q30886165 | Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis |
| Q39491071 | Distinct E2F-mediated transcriptional program regulates p14ARF gene expression |
| Q40654315 | Distinct patterns of gene expression induced by viral oncogenes in human embryonic brain cells |
| Q38191796 | Drugging the p53 pathway: understanding the route to clinical efficacy |
| Q24537475 | Dual promoters control the cell-specific expression of the human cell death-inducing DFF45-like effector B gene |
| Q24672780 | E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints |
| Q54393600 | E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. |
| Q34284001 | E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis |
| Q34922303 | E2F1 pathways to apoptosis |
| Q24674252 | E2f1, E2f2, and E2f3 control E2F target expression and cellular proliferation via a p53-dependent negative feedback loop |
| Q24295046 | EAPP, a novel E2F binding protein that modulates E2F-dependent transcription |
| Q28377993 | Endogenous endothelial cell nitric-oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53 |
| Q57570317 | Epigenetic Mechanisms in Cancer Formation and Progression |
| Q37314994 | Epigenetic cross-talk between DNA methylation and histone modifications in human cancers |
| Q36801625 | Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. |
| Q83829640 | Epigenetic mechanisms in Alzheimer's disease |
| Q39239707 | Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia |
| Q39090345 | Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation |
| Q35857807 | Epigenetics of kidney cancer and bladder cancer |
| Q41076603 | Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. |
| Q43002037 | Events in the immortalizing process of primary human mammary epithelial cells by the catalytic subunit of human telomerase |
| Q34708842 | Expression of CYP2W1 in colon tumors: regulation by gene methylation. |
| Q37004455 | Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma |
| Q27853395 | Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection |
| Q54424489 | HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas. |
| Q33743767 | High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma |
| Q36394792 | Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation. |
| Q37317281 | Human papillomavirus oncogenic E6 protein regulates human β-defensin 3 (hBD3) expression via the tumor suppressor protein p53. |
| Q36316169 | Hypermethylation of the 5' CpG island of the p14ARF flanking exon 1β in human colorectal cancer displaying a restricted pattern of p53 overexpression concomitant with increased MDM2 expression |
| Q35029017 | Hypermethylation pathways to colorectal cancer. Implications for prevention and detection |
| Q42791337 | INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene |
| Q48505500 | Immunohistochemical markers for prognosis of ependymal neoplasms |
| Q73171095 | Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer |
| Q40756082 | Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines |
| Q48022280 | Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway |
| Q33958412 | Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a) |
| Q34115920 | Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. |
| Q34283452 | Integration of the pRB and p53 cell cycle control pathways |
| Q35556958 | Interaction of the ARF tumor suppressor with cytosolic HSP70 contributes to its autophagy function |
| Q35185629 | Involvement of the INK4a/Arf gene locus in senescence |
| Q47262034 | Long non-coding RNA ANRIL in gene regulation and its duality in atherosclerosis |
| Q33811448 | Loss of heterozygosity at the Ink4a/Arf locus facilitates Abelson virus transformation of pre-B cells |
| Q80827612 | Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development |
| Q37268813 | Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo |
| Q36395100 | Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer |
| Q37620965 | Methods for genome-wide analysis of DNA methylation in intestinal tumors |
| Q34770530 | Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? |
| Q34378429 | Methylation and colorectal cancer |
| Q28364163 | Methylation matters |
| Q47791754 | Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. |
| Q35596441 | Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer |
| Q40822748 | Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer |
| Q40341155 | Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma |
| Q46071071 | Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors |
| Q33739268 | Modeling malignant melanoma in mice: pathogenesis and maintenance |
| Q47445963 | Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma |
| Q34245527 | Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. |
| Q74394147 | Myc requires distinct E2F activities to induce S phase and apoptosis |
| Q53380068 | Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. |
| Q36454901 | PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis. |
| Q39584815 | Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1 |
| Q34562906 | Polymorphisms in promoter sequences of MDM2, p53, and p16 genes in normal Japanese individuals |
| Q36139948 | Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor |
| Q79175646 | Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors |
| Q34995366 | Progressive silencing of p14ARF in oesophageal adenocarcinoma |
| Q28189476 | Proliferation, cell cycle and apoptosis in cancer |
| Q45040366 | Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. |
| Q39909636 | Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer |
| Q35533826 | Quantification of epigenetic biomarkers: an evaluation of established and emerging methods for DNA methylation analysis |
| Q55474425 | Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. |
| Q54290197 | Ratio of expression of p16INK4a to p14ARF correlates with the progression of non-small cell lung cancer. |
| Q33961286 | Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor |
| Q46775969 | Regulation of the INK4a/ARF locus by histone deacetylase inhibitors |
| Q36572080 | Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. |
| Q35964783 | Relationships between p14ARF Gene Methylation and Clinicopathological Features of Colorectal Cancer: A Meta-Analysis |
| Q35146155 | Relevance of DNA methylation in the management of cancer |
| Q42490218 | Repression of BRCA1 through a feedback loop involving p53. |
| Q37149722 | Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities |
| Q37309797 | Role for tissue-dependent methylation differences in the expression of FOXE1 in nontumoral thyroid glands |
| Q37111920 | Role of DMP1 and its future in lung cancer diagnostics |
| Q34569515 | Role of molecular biology in the follow-up of patients who have Barrett's esophagus |
| Q24804591 | Selection of novel mediators of E2F1-induced apoptosis through retroviral expression of an antisense cDNA library |
| Q35860006 | Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia |
| Q53404327 | Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. |
| Q40529860 | Stability of nucleolar versus non-nucleolar forms of human p14(ARF). |
| Q38838490 | Stabilization of the p53-DNA Complex by the Nuclear Protein Dmp1α. |
| Q40104894 | Targeted DNA methylation in human cells using engineered dCas9-methyltransferases. |
| Q33947609 | Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death |
| Q38059739 | Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy |
| Q41819519 | The ARF tumor suppressor can promote the progression of some tumors. |
| Q37220014 | The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis |
| Q33543982 | The DNA methylation paradox |
| Q33828920 | The E2F transcription factors: key regulators of cell proliferation |
| Q34283464 | The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth |
| Q28217021 | The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator |
| Q28594399 | The absence of Msh2 alters abelson virus pre-B-cell transformation by influencing p53 mutation |
| Q33771774 | The cellular response to p53: the decision between life and death |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q34646667 | The genetics of the E2F family of transcription factors: shared functions and unique roles |
| Q42631806 | The human ARF tumor suppressor senses blastema activity and suppresses epimorphic tissue regeneration |
| Q22010018 | The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors |
| Q40767774 | The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. |
| Q78840634 | The mouse Ink4a/Arf locus: a p53 pile-up at a tumour surveillance crossroads? |
| Q40811047 | The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters |
| Q39451034 | The p21(WAF1/CIP1) promoter is methylated in Rat-1 cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene |
| Q53412655 | The paradox of E2F1: oncogene and tumor suppressor gene. |
| Q28258178 | The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1 |
| Q24536177 | The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity |
| Q50335773 | The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia |
| Q40935835 | Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus |
| Q78732223 | Transcriptional control of the RECK metastasis/angiogenesis suppressor gene |
| Q38300895 | Transcriptional repression by p53 through direct binding to a novel DNA element |
| Q35155473 | Transgenic and knockout mice models to reveal the functions of tumor suppressor genes |
| Q24599468 | Twist is a potential oncogene that inhibits apoptosis |
| Q33955751 | UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer |
| Q42833059 | Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis |
| Q77448981 | [Cyclin dependent kinase inhibitors and replicative senescence] |
| Q73897120 | p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53 |
| Q39750802 | p14ARF interacts with E2F factors to form p14ARF-E2F/partner-DNA complexes repressing E2F-dependent transcription |
| Q47307403 | p19Arf Inhibits Aggressive Progression of H-ras driven Hepatocellular Carcinoma |
| Q34377287 | p53 Family and Cellular Stress Responses in Cancer |
| Q33936026 | p53 and ARF: unexpected players in autophagy |
| Q37602510 | p53 and E2f: partners in life and death |
| Q39488131 | p53 binds to and is required for the repression of Arf tumor suppressor by HDAC and polycomb |
| Q43249196 | p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. |
| Q42362115 | p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance |
Search more.